These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 29649374)

  • 41. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
    Bron L; Romero P
    Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current role of gene therapy in head and neck cancer.
    Ganly I; Soutar DS; Kaye SB
    Eur J Surg Oncol; 2000 Jun; 26(4):338-43. PubMed ID: 10873352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
    Juergens RA; Bratman SV; Tsao MS; Laurie SA; Sara Kuruvilla M; Razak AR; Hansen AR
    Cancer Treat Rev; 2017 Mar; 54():43-57. PubMed ID: 28192747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New advances in molecular approaches to head and neck squamous cell carcinoma.
    Sahu N; Grandis JR
    Anticancer Drugs; 2011 Aug; 22(7):656-64. PubMed ID: 21178766
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
    Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
    Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
    Tsimberidou AM
    Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genomics-Guided Immunotherapy for Precision Medicine in Cancer.
    Mukherjee S
    Cancer Biother Radiopharm; 2019 Oct; 34(8):487-497. PubMed ID: 31314580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Schoppy DW; Sunwoo JB
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1033-43. PubMed ID: 26568546
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunotherapy for head and neck squamous cell carcinoma].
    Bron L; Romero P
    Rev Med Suisse; 2006 Oct; 2(81):2216-9. PubMed ID: 17076151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EGFR-targeted therapies in the post-genomic era.
    Xu MJ; Johnson DE; Grandis JR
    Cancer Metastasis Rev; 2017 Sep; 36(3):463-473. PubMed ID: 28866730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The potential for tumor suppressor gene therapy in head and neck cancer.
    Birkeland AC; Ludwig ML; Spector ME; Brenner JC
    Discov Med; 2016 Jan; 21(113):41-7. PubMed ID: 26896601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of genetic targets on therapy in head and neck squamous cell carcinoma.
    Chaikhoutdinov I; Goldenberg D
    Adv Exp Med Biol; 2013; 779():165-77. PubMed ID: 23288639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Genomic characterization of head and neck squamous cell carcinoma: Impact and challenges for therapeutic management].
    Saada-Bouzid E; Milano G; Thariat J
    Bull Cancer; 2018 Sep; 105(9):820-829. PubMed ID: 29937334
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunotherapy in head and neck cancer: current practice and future possibilities.
    Agada FO; Alhamarneh O; Stafford ND; Greenman J
    J Laryngol Otol; 2009 Jan; 123(1):19-28. PubMed ID: 18761763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Harnessing massively parallel sequencing in personalized head and neck oncology.
    Jessri M; Farah CS
    J Dent Res; 2014 May; 93(5):437-44. PubMed ID: 24557572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gene therapy for head and neck cancers.
    Lamont JP; Kuhn JA; Nemunaitis JJ; McCarty TM
    Oncology (Williston Park); 2001 Mar; 15(3):303-8; discussion 311-4. PubMed ID: 11301829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequencing the head and neck cancer genome: implications for therapy.
    Sun W; Califano JA
    Ann N Y Acad Sci; 2014 Dec; 1333():33-42. PubMed ID: 25440877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.
    Horton JD; Knochelmann HM; Day TA; Paulos CM; Neskey DM
    Trends Cancer; 2019 Apr; 5(4):208-232. PubMed ID: 30961829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.